Roche Holding AG
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-29.1% vs price
Base Case (Median)
34.8% vs price
Bull Case (75th pct.)
44.6% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $73.69 | 34.8% | High (40%) |
| PE Comparable | $77.44 | 41.7% | Medium (25%) |
| Growth Trajectory DCF | $83.20 | 52.2% | Medium (20%) |
| Graham Number | $20.31 | -62.8% | Medium (40%) |
| EV/EBITDA | $33.80 | -38.2% | Medium (20%) |
| EV/FCF | $80.69 | 47.6% | Medium (20%) |
| Earnings Power Value | $43.71 | -20.1% | Medium (50%) |
Based on 7 out of 8 methods, RHHBY appears fairly valued at the current price of $54.67. The base case fair value of $73.69 implies 34.8% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.